HKD 1.32
(0.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 372.02 Million CNY | 67.39% |
2022 | 222.25 Million CNY | 102.19% |
2021 | 109.92 Million CNY | -94.43% |
2020 | 1.97 Billion CNY | 240.24% |
2019 | 579.74 Million CNY | 167.8% |
2018 | 216.48 Million CNY | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 351.8 Million CNY | 0.0% |
2024 Q1 | 351.8 Million CNY | -5.43% |
2023 Q4 | 372.02 Million CNY | 0.0% |
2023 FY | 372.02 Million CNY | 67.39% |
2023 Q3 | 372.02 Million CNY | 20.88% |
2023 Q2 | 307.77 Million CNY | 0.0% |
2023 Q1 | 307.77 Million CNY | 38.48% |
2022 Q4 | 222.25 Million CNY | 0.0% |
2022 Q1 | 109.24 Million CNY | -0.61% |
2022 Q2 | 109.24 Million CNY | 0.0% |
2022 FY | 222.25 Million CNY | 102.19% |
2022 Q3 | 222.25 Million CNY | 103.44% |
2021 Q1 | 159.96 Million CNY | -91.89% |
2021 FY | 109.92 Million CNY | -94.43% |
2021 Q2 | 159.96 Million CNY | 0.0% |
2021 Q4 | 109.92 Million CNY | 0.0% |
2021 Q3 | 109.92 Million CNY | -31.29% |
2020 FY | 1.97 Billion CNY | 240.24% |
2020 Q4 | 1.97 Billion CNY | 0.0% |
2020 Q1 | - CNY | -100.0% |
2019 Q4 | 579.74 Million CNY | 0.0% |
2019 FY | 579.74 Million CNY | 167.8% |
2018 FY | 216.48 Million CNY | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Uni-Bio Science Group Limited | 152.81 Million HKD | -143.44% |
CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | 94.729% |